HAS Healthcare Advanced Synthesis Acquires Cerbios-Pharma (Backed by 65 Equity Partners)

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.

November 11, 2021

Pharmaceuticals

Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.

ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera

November 17, 2023

Healthcare Services

ARCHIMED has acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and merged them to create Symbio Proinnovera, a specialized dermatology-focused CRO. The combined group will offer end-to-end dermatology consulting, formulation, testing and clinical research across North America and Europe, with founders rolling equity into the new platform and ARCHIMED-appointed operating partners joining the board to drive growth and further acquisitions.

Biosynth Acquires Cambridge Research Biochemicals (CRB)

May 9, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.